In combination with gilteritinibPrimary objectives: to assess safety, tolerability and RP2DSecondary objectives: to assess efficacy MADRID, Spain and BOSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in its Phase Ib trial of iadademstat in combination with gilteritinib
A highly selective HDAC-6 inhibitorRescues motor-neuronal deficiencies in a Charcot-Marie-Tooth modelTo start IND enabling studies MADRID, Spain and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the nomination of ORY-4001, a selective histone deacetylase 6 (HDAC-6) inhibitor, as clinical development c
Monday, February 27th at 10am ETMADRID, Spain and BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it will host a virtual panel discussion, featuring Dr. Dyanna Phillips Domilici (Adams Clinical & Copley Clinical), Dr. med. Peter Hahn (Investigator & Neurology Specialist, emovis), and Dr. Olga Salame